Actavis CEO: We may be big, but we don't want to be Big Pharma

Big Pharma or "growth pharma"? Actavis ($ACT) CEO Brent Saunders is aiming for the latter. Though his company is expected to rank among the industry's top 10 after closing its Allergan ($AGN) buy later this year, Saunders says Actavis won't act like a Big Pharma. What's the difference? He has some ideas. Report

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.